Paraneoplastic stiff person syndrome with small cell carcinoma of the bladder and anti-Ri antibodies

•The stiff person syndrome (SPS) is difficult to diagnose and to treat.•Paraneoplastic SPS with anti-Ri antibodies is less known.•Early antitumoral therapy should be the first step in these cases.•SPS has not been described in bladder cancer to date.•This case report expands the spectrum of paraneop...

Full description

Saved in:
Bibliographic Details
Published in:Clinical neurology and neurosurgery 2018-10, Vol.173, p.194-195
Main Authors: de Albóniga-Chindurza, Asier, Riva, Elena, Jiménez-Huete, Adolfo, Graus, Francesc, Franch, Oriol
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Autoantibodies - immunology
Bladder cancer
Cancer therapies
Carcinoma, Small Cell - complications
Chemotherapy
Electromyography
Glutamate Decarboxylase - immunology
Humans
Immunoglobulins
Lymphatic system
Male
Middle Aged
Nervous System Diseases - complications
Nervous System Diseases - immunology
Neuroimmunology
Neurology
Paraneoplastic
Stiff person
Stiff-Person Syndrome - complications
Urinary Bladder - immunology
Urinary Bladder Neoplasms - complications
Urinary Bladder Neoplasms - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The stiff person syndrome (SPS) is difficult to diagnose and to treat.•Paraneoplastic SPS with anti-Ri antibodies is less known.•Early antitumoral therapy should be the first step in these cases.•SPS has not been described in bladder cancer to date.•This case report expands the spectrum of paraneoplastic SPS. The stiff person syndrome is a rare neurological disorder, difficult to diagnose and to treat. Paraneoplastic patients usually present amphiphysin antibodies but the association with anti-Ri antibodies is less known. We present a case report of paraneoplastic SPS, small cell carcinoma of the bladder and anti-Ri antibodies.
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2018.08.020